MORRIS PLAINS, N.J., Oct. 16, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced it has received notice that its patent application for “Monoclonal antibody hPAM4" will issue as U.S. patent no. 7,282,567 today. The patent covers the composition of matter for the MUC1-antigen binding humanized antibody and its use in the diagnosis and therapy of pancreatic cancers.
